Treatment for Patients with Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

What we are studying

This research looks at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the body and increase the risk of developing blood clots. The purpose of this study is to look at the effectiveness of giving patients who have been diagnosed with ET and PV a study drug regimen using Aspirin and interferon alfa-2a instead of the standard treatment drug called Hydroxyurea, for whom this drug may not be suitable.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • A diagnosis of ET or PV
  • EITHER be intolerant or resistant to Hydroxyurea

What is involved

  • Physical exam
  • Blood tests
  • Bone marrow aspiration/biopsy/cytogenetics
  • EKG (electrocardiogram)
  • Quality of Life questionnaires

Compensation

Parking validation will be provided for all study-related visits

Contact Information

Study Coordinator
Cindy Miller
Email
cytmill@wakehealth.edu
Phone
336-713-6770

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.